NCT06924229

Corneal Changes in Estrogen-Dependent Breast Cancer After Hormonal Treatment

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Sohag University · Academic / Other
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Aromatase inhibitors (AI) therapy is the treatment of choice for estrogen receptor-positive breast cancer (BC). While AIs effectively suppress tumor growth, estrogen deprivation may have negative impacts on the eyes. This work evaluated the anterior segment changes in estrogen-dependent BC after hormonal treatment.

Detailed description

Aromatase inhibitors (AI) therapy is an important treatment for estrogen receptor-positive breast cancer (BC). This work evaluated the eye anterior segment changes in estrogen-dependent BC after hormonal treatment. This cross-sectional study was conducted on female patients aged ≥18 who received treatment for BC. Patients were evaluated by a number of tests to determine the effects on the cornea and the lacrimal system

Conditions

• Braest Cancer
• Dry Eye

Interventions

Type	Name	Description
DRUG	Hormonal treatment	hormonal treatment for breast cancer

Timeline

• Start date: 2024-06-01
• Primary completion: 2025-01-01
• Completion: 2025-01-01
• First posted: 2025-04-11
• Last updated: 2025-04-11

Locations

1 site across 1 country: Egypt